U.S. FDA Issues Complete Response Letter for Baricitinib

U.S. FDA Issues Complete Response Letter for Baricitinib


The letter indicates that the FDA is unable to approve the application in its current form. Specifically, the FDA indicated that additional clinical data are needed to determine the most appropriate doses.



from Biotech News